1Tang Y, Osawa H, Onuma H, et al. Phosohodiesterase 3B gene expression is enhanced in the liver but reduced in the adipose tissue of obese insulin risistance db/ db mouse[J] .Diabetes Res din pract, 2001, 54(3): 145
2Sun Yang, Liu Sha, Ferguson Sandra, et al. Phosphoenolpyruvate carboxykinase overexpression selectively attenuates insulin signaling and hepatic insulin sensitivity in transgenic mice[J]. J Biol Chem,2002, 277(26):23 301
3Catalano Patrick M, Nizielski Steven E, Shao Jianhua, et al. Downregulated IRS-1 and PPAR gamma in obese women with gestational diabetes: relationship to FFA during pregnancy[J]. Am J Physiol Endocrinol Metab, 2002, 282(3): E522
4Lucy H, Clerk, Stephen Rattigan, et al. Lipid infusion impairs physiologic insulin-mediated capillary recruitment and muscle glucose uptake in vivo[J]. Diatetes,2002, 51:1 138
5Boden G, Shulman GI.Free fatty acids in obesity and type 2diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction[J] .Eur J Clin Invest,2002, 32(Suppl 3): 14
6Itani SI, Ruderman NB, Schmieder F, et al. Lipid-induced insulin resistance with changes in diacylglycerol, protein kinase C and I ' kappa B- alpha [J]. Diabetes, 2002, 51(7): 2002
7Lam Tony KT, Yoshii Hidenori, Haber C Andrew, et al. Free fatty acid-induced hepatic insulin resistance: a potential role for protein kinase C- delta[J] .Am J Physiol Endocrinol Metab, 2002, 283(4) :E682
8Shaoming Song, Sofianos Andrikopoulos. Mechanism of fatinduced hepatic gluconeogenesis: effect of metformin[J]. Am J Physiol Endocrinol Metab, 2001,281: E275
9Boden G , Cheng P, Stein TP, et al. FFA cause hepatic insulin resistance by inhibiting insulin suppression of glycogenolysis [J]. Am J Physiol Endocrinol Metab, 2002, 283(1) :E12
10Boden G. Free fatty acids, insulin resistance, and type 2 diabetes mellitus[J]. Proc Assoc Am Physicians, 1999, 111(3):241
2Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM[J]. Diabetes, 1997, 46(1): 3- 10.
3Chen X, Boden G. Effects of fatty acids on insulin secretion in patients with NIDDM[J]. Diabetes, 1996, 45: 311.
4Carpentier A, Mittelman SD, Bergman RN, et al. Prolonged elevation of plasma free fatty acids impairs pancreatic beta-cell function in obese nondiabetic humans but not in individuals with type 2 diabetes[J]. Diabetes, 2000, 49(3): 399-408.
5Zhou YP, Berggren PO, Grill VE. A fatty acid-induced decrease in pyruvate dehydrongenase activity is an important determinant of Bcell dysfunction in obese diabetic islets[J]. Diabetes, 1996, 45: 580 - 586.
6Wang MY, Koyama K, Shimabukuro M, et al. Ob-Rb gene transfer to leptin-resistant islets reverses diabetogenic phenotype [ J ]. Proc Natl Acad Sci USA, 1998, 95: 714-718.
7Shimabukuro M, Zhou YT, Lee Y, et al. Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats[J]. J Biol Chem, 1998, 273: 3547-3550.
8Shimabukuro M, Ohneda M, Lee Y, et al. Role of nitric oxide in obesity-induced beta cell disease[J]. J Clin Invest, 1997, 100:290 - 295.
9Shimabukuro M, Koyaroa K, Lee Y, et al. Leptin-or troglitazone-induced lipopenia protects islets from interleukin 1beta cytotoxicity[J]. J Clin Invest, 1997, 100: 1750-1754.
10Solow BT, Harada S, Goldstein BJ, et al. Differential modulation of the tyrosine phosphorylation state of the insulin receptor by IRS (insulin receptorsubunit) proteins[J].Mol Endocrinol, 1999, 13(10): 1784-1798.
